Return of fertility after treatment for nonseminomatous testicular cancer: changing concepts.
We studied the return of ejaculation in 31 patients who had undergone retroperitoneal lymphadenectomy for stage I or II nonseminomatous germ cell testicular cancer. Ejaculation returned spontaneously in 13 patients and was restored by sympathomimetic drugs in 5 of 8 patients treated. Both patients known to have tried to father a child succeeded. We also studied the effects of chemotherapy (vinblastine and bleomycin with or without cisplatin) in 34 patients, 24 of whom also had undergone retroperitoneal lymphadenectomy. Although chemotherapy profoundly depressed spermatogenesis during treatment 75 per cent of the patients tested 18 months or more after completion of treatment had some return of function, as evidenced by normal follicle-stimulating hormone levels and/or the presence of live sperm in the ejaculate. We concluded that it is possible to perform a therapeutically sound retroperitoneal lymphadenectomy for low stage nonseminomatous testicular cancer that permits return of ejaculation in many patients and that spermatogenesis recovers in a significant number of patients treated for this cancer with modern chemotherapy. Thus, traditional beliefs that operative and drug treatment of nonseminomatous testicular cancer invariably causes infertility must be revised.
D000970:Antineoplastic Agents / Q000009:adverse effects; D004542:Ejaculation / Q000187:drug effects; D005298:Fertility / Q000187:drug effects; D006728:Hormones / Q000097:blood; D006801:Humans; D008197:Lymph Node Excision; D008207:Lymphatic Metastasis; D008297:Male; D009373:Neoplasms, Germ Cell and Embryonal / Q000503:physiopathology / Q000628:therapy*; D012186:Retroperitoneal Neoplasms / Q000601:surgery; D013091:Spermatogenesis / Q000187:drug effects; D013736:Testicular Neoplasms / Q000503:physiopathology / Q000628:therapy*
D000970:Antineoplastic Agents; D006728:Hormones